ically with the HIV capsid protein, CypB binds CAML The selection of specific prolyl peptide bonds in natumotif, increases the transcriptional activity of c-Myb from the CD34 but not the mim-1 promoter suggesting ral protein substrates is likely to involve interactions of the PPIases with additional residues lying on either side that phosphorylation of Ser528 negatively regulates c-Myb activity (Miglarese et al., 1996) . Intriguingly, p100, of the Pro and perhaps elsewhere in the protein (Gamble et al., 1996) . In addition, each PPIase family displays a a conserved transcriptional coactivator containing a Myb-related EVES motif, interacts via its EVES motif with different specificity for the residue preceding the Pro: the FKBPs prefer a Pro preceded by a bulky hydrophothe c-Myb DBD and decreases c-Myb transcriptional activity on a mim-1 reporter (Dash et al., 1996) . Possibly, bic residue, whereas the cyclophilins show little preference at this position. Parvulin, like the FKBPs, prefers phosphorylation of Ser528 increases p100 to c-Myb binding by dissociating the EVES domain from the DBD. a hydrophobic residue at the Ϫ1 position (Rahfeld et al., 1994) , but the Pin1/Ess1p subfamily of parvulin PPIases v-Myb was derived from c-Myb through the loss of N-terminal sequences including part of the first of the have three conserved basic residues that form an anion binding patch in the active site, which results in Pin1/ three repeats in the DBD, and the deletion of the C-terminal NRD leaving the AD intact (Figure 1 ). In addition to the Ess1p having a unique specificity for a phosphorylated Ser or Thr preceding the Pro (Ranganathan et al., 1997;  terminal truncations, v-Myb harbors 11 point mutations, four of which are located in the DBD. None of these Yaffe et al., 1997) . Indeed, Pin1 binds stably to a set of mitotic phosphoproteins, comprising many of the antipoint mutations is essential for v-Myb myeloblast transforming activity, but mutations in the DBD and AD are gens recognized by the MPM2 monoclonal antibody (Crenshaw et al., 1998; Shen et al., 1998 , 1997) .
The fact that c-Myb is negatively regulated by intramophosphopeptide substrate compared to the unphosphorylated form, underscoring the importance of the lecular association between the DBD and the NRD suggested that c-Myb could be activated by an enzyme phosphate (Yaffe et al., 1997) . The majority of the cyclophilins and FKBPs are cytoplasmic proteins, alknown to modify protein conformation. For this reason, Leverson and Ness (1998) examined the interaction bethough CypA, Cyp40, FKBP25, and FKBP52 may have dual nuclear and cytoplasmic localization (Dolinski and tween a cyclophilin family PPIase and c-Myb. They showed that c-Myb binds to Cyp40 in vitro, through Heitman, 1997). Pin1 is localized in the nucleus (Lu et al., 1996) , but it is not known whether other members interaction between the C-terminal tetratricopeptide (TPR) repeat domain of Cyp40 and the DBD of c-Myb. of the parvulin family are nuclear proteins.
Myb Family Transcription Factors
Addition of recombinant Cyp40 to a nuclear extract of Jurkat cells abolishes c-Myb DNA-binding activity dec-Myb was originally identified as the protooncogene that engendered the v-Myb oncogene of avian myelotected by a gel shift assay. This effect is reversed by CsA, which binds to and inactivates the N-terminal PPIblastosis virus, which induces a myeloblastic leukemia in chickens. c-Myb is a highly conserved 75-89 kDa ase domain of Cyp40. In contrast, Cyp40 does not bind to v-Myb, nor does it inhibit its DNA-binding activity transcription factor, which is essential for normal fetal hepatic hematopoiesis, but not for yolk sac hematopoiewhen added to a nuclear extract from AMV-transformed BM2 myeloblast cells. The failure of Cyp40 to bind to sis in the mouse (for review, see Ness, 1996) . The precise function of c-Myb in hematopoiesis is not clear, but it v-Myb is presumably accounted for by one or more of the point mutations in the v-Myb DBD. Interestingly, is presumed to involve regulation of genes involved in myeloid lineage commitment. c-Myb has three functhree of the altered residues map to a small region on the surface of the DBD (Ogata et al., 1994) , which pretional domains, an N-terminal DNA-binding domain (DBD, residues 38-192), a central acidic transactivation sumably provides part of the binding site for Cyp40. Leverson and Ness conclude that Cyp40 plays a role in domain (AD, residues 240-365), and a C-terminal negative regulatory domain (NRD, residues 400-570), which negative regulation of c-Myb function through its PPIase activity, and that the mutations in the v-Myb DNA-bindincludes a leucine zipper (Figure 1 ). c-Myb is the prototype for a large family of transcription factors with reing domain were selected to eliminate this negative regulation (Figure 1) . Indeed, the fact that the mutations in lated DNA-binding domains that contain two or three repeats each with a three-helix fold similar to that of the v-Myb DNA-binding domain prevent Cyp40 binding provides strong support for the physiological relevance the homeodomain. A consensus DNA-binding sequence (PyAACG/TG) has been established for the Myb DBD, of the interaction of c-Myb with Cyp40. Mutations in oncoproteins that vitiate negative regulation are a comand a number of genes that are targets for Myb activation (e.g., mim-1 and CD34) or repression (e.g., c-fms) mon principle of oncogenic activation (e.g., the loss of the C-terminal regulatory Tyr in c-Src), and the point have been identified. NRD residues 513-563, a conserved region that includes the EVES motif, interact with mutations in the Myb DBD provide another example. The finding that Cyp40 negatively regulates the DNAthe DBD (Dash et al., 1996) . c-Myb function is negatively regulated by this interaction. In principle, this could be binding activity of c-Myb in vitro raises a number of questions. Foremost is whether Cyp40 regulates c-Myb because the NRD-DBD interaction decreases DNAbinding activity, but this has not been rigorously tested.
transcriptional activity in the cell. Does c-Myb associate with Cyp40 in vivo? Does overexpression of Cyp40 deMutation of Ser528 in mouse c-Myb, which is a MAP kinase site and corresponds to the Ser in the EVES crease c-Myb transcriptional activation activity? Does
CsA increase c-Myb transcriptional activity using a rein mind that it has not been unequivocally established that Pin1's cell cycle function requires it to act as a porter gene assay? Do other cyclophilins or FKBPs (e.g., PPIase as opposed to simply binding to its phosphory-FKBP52 which also has TPR repeats) interact with lated targets. This is an important issue, because parc-Myb? Although CsA, an inhibitor of Cyp40 PPIase acvulin has much lower activity in protein folding assays tivity, prevents Cyp40 from inhibiting c-Myb DNA bindthan on peptide substrates (Scholz et al., 1997a) . The ing without blocking its binding to c-Myb, it is not strictly currently ascribed function of Pin1 is at the G2/M transiclear that Cyp40 PPIase activity is required to inhibit tion, but in principle it could also recognize substrates c-Myb DNA binding, since bound CsA might preclude for other proline-directed protein kinases, such as MAP a PPIase-independent interaction of the Cyp40 PPIase kinases, and thus have cell cycle independent functions. domain with the DBD. Ideally, a PPIase-deficient Cyp40
The fact that none of the yeast cyclophilins or FKBPs mutant should be tested in this system, but not all mutaare essential implies that these PPIases do not have tions that inactivate cyclophilins and FKBP PPIase activa critical nuclear function. However, although budding ity on peptide substrates abolish activity against protein yeast has no additional PPIases of these types, there substrates (Dolinski et al., 1997b; Scholz et al., 1997b) .
could be other novel types of PPIase. Nuclear function There is also the issue of whether Cyp40 has to associis increasingly recognized to involve the assembly and ate stoichiometrically with c-Myb or whether it acts catadisassembly of macromolecular complexes, and these lytically to decrease DNA binding. Is there a target Pro would make attractive targets for PPIases that could near the region mapped out on the surface of the DBD regulate protein-protein interactions through conformaby the v-Myb mutations, or does the target peptide bond tional changes. lie elsewhere in c-Myb, for instance in the hinge region in the AD, which contains a number of conserved prolines?
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